**Core Concept**
The treatment of choice for pneumocystis carinii pneumonia (PCP) involves targeting the pathogen *Pneumocystis jirovecii*, which primarily affects immunocompromised patients. The underlying principle is to use antimicrobial agents that can effectively eradicate the organism.

**Why the Correct Answer is Right**
The correct answer is based on the use of trimethoprim-sulfamethoxazole (TMP-SMX), which is the first-line treatment for PCP due to its ability to inhibit folic acid synthesis in the pathogen. This combination is effective against *P. jirovecii* and is considered the standard of care.

**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect because it is not specified, but other options like pentamidine are considered alternative treatments, not the first line.
**Option B:** Incorrect as it is not the primary choice for PCP treatment.
**Option C:** Incorrect because, although an antibiotic, it is not typically used for PCP.
**Option D:** Incorrect as it is not the preferred treatment.

**Clinical Pearl / High-Yield Fact**
A key point to remember is that TMP-SMX is not only used for treatment but also for prophylaxis in high-risk patients, such as those with HIV/AIDS.

**Correct Answer:** Correct Answer: D. Trimethoprim-sulfamethoxazole.